Treatments and outcomes of adult patients with TP53-mutated acute myeloid leukemia (AML) in the real-life –Report of the prospective french observational ALFA-PPP study.
Jean-Baptiste Micol(Institut Gustave Roussy), Elsa Bernard(Inserm), Claude Preudhomme(Centre Hospitalier Universitaire de Lille), Sylvain Chantepie(Centre Hospitalier Universitaire de Caen Normandie), Laurène Fenwarth(Inserm), Christophe Willekens(Université Paris-Saclay), Renaud Buffet(Unit of Functional and Adaptive Biology), Delphine Lebon(Centre Hospitalier Universitaire Amiens-Picardie), Ahmad Aljijakli(Centre Hospitalier Victor Dupouy), Hervé Dombret(European Union), Emmanuel Raffoux(Inserm), Ramy Rahmé(Université Paris Cité), Laure Farnault(Aix-Marseille Université), Mathieu Leclerc(Hôpitaux Universitaires Henri-Mondor), Alexandra Coelho(Institut de Recherche et Coordination Acoustique Musique), Thomas Cluzeau(Centre Hospitalier Universitaire de Nice), Nicolas Duployez(Inserm), Dominique Penther(Inserm), Marie Sébert(Hôpital Saint-Louis), Jean-Valère Malfuson(Hôpital d'instruction des Armées Percy), Raphaël Itzykson(Université Paris-Sud), Claire Bories(Guy's and St Thomas' NHS Foundation Trust), Stéphane de Botton(Université Paris-Saclay)
Cited by 1
Related Papers
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
|Cell|2004|3.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k